328 W. Claiborne St.
P.O. Box 964
Monroeville, Alabama 36460
(251) 575-4203
Health Policy & Advocacy
Basic InformationMore InformationLatest News
Many Dermatology Guideline Authors Get Industry PaymentsDoctors Urged to Speak With Patients About FirearmsStates That Make You Wait to Buy Guns Have Fewer Deaths: StudyHomicides Devastate Black Communities, But Prevention Gets Little FundingBetter Patient Communication Needed After Urgent CareQuality Issues for Both Paper-, Electronic-Based Health RecordsRide-Sharing Services Could Cut Alcohol-Related CrashesLow-Cost Services a Major Player in Unnecessary Health SpendingMedical License Questions Sway Doctors' Mental Health Help'Heat-Not-Burn Cigarettes' Aiming for U.S. MarketFDA Approves Test to Screen Donated Blood for Zika21 Percent of Americans Report Experiencing a Medical ErrorUber Can Help Cut Car Crashes, But Not EverywhereThe Unexpected Faces of the UninsuredHealth Tip: Giving BloodCommunication Program Doesn't Raise Hospital Liability CostsSame Pregnancy Meds Can Cost $200 -- or $11,000Americans More Open About Mental Health Issues, But Stigma Lingers1 in 5 Have Been Hit By a Medical Error, Survey ShowsOpioid Manufacturers to Provide Doctor TrainingPatients' E-Records Still Not Widely AvailableU.S. Gun Injuries Nearing $3 Billion in ER, Hospital CostsState Laws Can Promote Hepatitis C Virus ScreeningTeens Mixed Up With the Law May Fall Through Medicaid CracksState Policies Can Reduce Alcohol-Related MurdersCDC Launches Opioid Campaign in Hard-Hit StatesU.S. Pays a Hefty Price for ObesityBlacks, Elderly Missing From U.S. Cancer Clinical TrialsFood Stamp Benefits May Lower Health Care CostsDrone Sets New Record for Transporting Blood SamplesGun Injuries Add Millions of Dollars to Hospital CostsACP Does Not Support Legalization of Assisted SuicideAAP: Few Doctors Provide Firearm Injury Prevention Info in ER9 of 10 Docs Unprepared to Prescribe MarijuanaThis Mistake Can Cost Athletes' Lives in Cardiac ArrestDrills Assess ER Response to Communicable DiseaseDo Nursing Home Workers Change Gloves Often Enough?Minorities Exposed to Dirtier Air, U.S. Study FindsPhysicians Tweeting About Drugs May Have Conflict of InterestHealth Tip: Overcoming the Obesity EpidemicU.S. Military Surgeons Helped More Than 6,000 Afghan AdultsWhat You Can Do to Help Fight the Opioid EpidemicAre Physicians Obligated to Help on Planes?Median Cost of Cancer Drug Development $648.0 MillionDoes Study Claim a Cure? Beware of Scientific 'Spin'Vaccine Campaign in Poor Countries to Save 20 Million LivesThird Dose of MMR Vaccine Could Help Curb Mumps OutbreaksDocs Should Be Aware of Family Beliefs Regarding NondisclosureIncrease in Medical Exemptions From Immunization in CaliforniaMailed Invitations Increase CRC Screening Completion
Related Topics

Health Insurance

Blacks, Elderly Missing From U.S. Cancer Clinical Trials

HealthDay News
by By Dennis ThompsonHealthDay Reporter
Updated: Sep 25th 2017

new article illustration

MONDAY, Sept. 25, 2017 (HealthDay News) -- Four out of five participants in cancer clinical trials are white, a discrepancy that calls into question whether other races and ethnicities are receiving good cancer treatment, researchers say.

Women and the elderly also are underrepresented in clinical trials, according to the new findings.

Prior studies have shown that the effectiveness of cancer treatment can vary based on a person's race, gender and age, said lead researcher Dr. Narjust Duma.

Despite this, clinical trials have failed to successfully recruit a diverse patient population upon whom to test new drugs and therapies, said Duma, a hematology/oncology fellow at the Mayo Clinic, in Rochester, Minn.

"All the data we're using to guide cancer treatment is for one type of patient," she said.

Duma undertook this study after a conversation with a black lung cancer patient about possible chemotherapy treatments.

"He asked, 'Where are the numbers about me?'" Duma recalled. "Where are the numbers about African-Americans? What are the chances we respond to treatment?"

A cursory look at chemotherapy research revealed that only a handful of blacks had been included in clinical trials involving hundreds of people, Duma said.

To explore the issue further, Duma and her colleagues analyzed enrollment data from all U.S. cancer therapy trials completed between 2003 and 2016, winding up with more than 55,000 participants.

Of those patients, 83 percent were white, 6 percent were black, just over 5 percent were Asian, almost 3 percent were Hispanic, and around 2 percent were classified as "other," researchers found.

The Hispanic numbers are particularly troubling, given that they currently make up 16 percent to 20 percent of the U.S. population and that proportion is increasing, Duma said.

"That's one-third of the U.S. population, and we have close to zero information about how to treat cancer in those patients," Duma said.

Researchers also found that only 36 percent of patients were aged 65 and older, even though cancer risk increases dramatically with age.

Finally, women were underrepresented in clinical trials for melanoma (just 35 percent), lung cancer (39 percent), and pancreatic cancer (40 percent).

Not including these folks in clinical trials means that doctors are not fully equipped to treat all the various types of cancer that can strike different groups, said Dr. Christopher Li, a research professor of epidemiology with Fred Hutchinson Cancer Research Center in Seattle.

"If these populations are underrepresented in clinical trials, there will also be an underrepresentation of the types of cancer that we know disproportionately affect them," Li said. For example, black and Hispanic women are much more likely to be diagnosed with aggressive breast cancer.

"Therefore, we will have less knowledge around the effectiveness of treatment that might be specific for these different forms of the disease," Li continued.

Duma said research already has revealed some differences:

  • Blacks appear to metabolize some chemotherapy drugs more quickly, meaning they might need larger doses than other groups.
  • The female hormone estrogen plays a significant role in how well tumors respond to cancer drugs.
  • Elderly patients are more likely to suffer crippling side effects from their cancer treatment, and rebound from them less easily.

America's history of unethical experimentation on minority groups prompts many to avoid participation in clinical trials, particularly blacks, Duma and Li said.

They cited the Tuskegee Study, started in 1932, in which black men were denied treatment for syphilis over four decades so researchers could observe the long-term effects of the venereal disease.

"Our country is still living with the legacy of things like Tuskegee," Li said. Fears associated with being involved in research keep certain people from participating in clinical trials, he noted.

To overcome these concerns, the leaders of clinical trials need to provide more access to their studies through community-based hospitals, rather than the collegiate research hospitals where most trials are conducted, Li said.

Researchers also should recruit spokespeople from various racial and ethnic groups "who have participated in research trials who can talk with other members of their community in ways they can trust," Li added.

Duma said clinical trials could provide more support to elderly participants -- perhaps helping them keep their medications organized and providing money to those living on a fixed income.

And medical journals can help promote diversity by refusing to publish trials unless researchers provide tables indicating the race, age and sex of all participants, along with any reasons why certain groups are underrepresented, Duma said.

The findings were presented Monday at an American Association for Cancer Research meeting, in Atlanta. Until published in a peer-reviewed medical journal, research presented at meetings is usually considered preliminary.

More information

For more on clinical trials, visit the U.S. National Cancer Institute.

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net